{"id":"067a0ccc-781e-566d-9205-52d816a3b7cc","stable_key":"4910e17b-aaec-52cd-b9e5-caca85d817ee:red-yeast-rice-xuezhikang-events","predicate":"reduces_tested","statement":"Over an average 4.5 years, major coronary events occurred in 5.7% of the Xuezhikang group versus 10.4% of placebo in nearly 5,000 Chinese patients with prior myocardial infarction.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"negative","is_public":true,"mechanism_event_id":"c5c98e0c-2b05-5111-a711-25d0f996e891","mechanism_event_label":"A specific extract had cardiovascular-outcome evidence in a defined population.","subject":{"id":"6f84ef7e-28eb-577f-87b9-046fa73090fb","slug":"xuezhikang-ccsps","display_name":"Xuezhikang preparation in the coronary secondary-prevention trial","entity_type_key":"drug"},"object":{"id":"6077d044-6b10-5573-b01f-52628b3d3118","slug":"human-xuezhikang-coronary-events","display_name":"Major coronary events in the Xuezhikang secondary-prevention trial","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"c5c98e0c-2b05-5111-a711-25d0f996e891","stable_key":"4910e17b-aaec-52cd-b9e5-caca85d817ee:red-yeast-rice-xuezhikang-events-event","event_type":"observed_relationship","label":"A specific extract had cardiovascular-outcome evidence in a defined population.","description":"Over an average 4.5 years, major coronary events occurred in 5.7% of the Xuezhikang group versus 10.4% of placebo in nearly 5,000 Chinese patients with prior myocardial infarction.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"6f84ef7e-28eb-577f-87b9-046fa73090fb","slug":"xuezhikang-ccsps","display_name":"Xuezhikang preparation in the coronary secondary-prevention trial","entity_type_key":"drug"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"6077d044-6b10-5573-b01f-52628b3d3118","slug":"human-xuezhikang-coronary-events","display_name":"Major coronary events in the Xuezhikang secondary-prevention trial","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""}]},"contexts":[{"dimension":"evidence_access","value_text":"Primary abstract","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Randomized secondary-prevention trial; partially purified Xuezhikang preparation.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Not proof for arbitrary supplements, primary prevention or isolated pigment effects; event reduction is not itself a molecular mechanism.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Red yeast rice collection; species, compartment, exposure, co-substrates and manipulation remain explicit.","comparator":null,"unit":null,"notes":"","entity":{"slug":"red-yeast-rice","display_name":"Red yeast rice","entity_type_key":"chemical_species"}},{"dimension":"plain_language","value_text":"A specific extract had cardiovascular-outcome evidence in a defined population.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"[18549841] Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction. · 2008 · https://pubmed.ncbi.nlm.nih.gov/18549841/ · DOI 10.1016/j.amjcard.2008.02.056","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"98be4c1c-14e6-5aa6-89b6-330fc562885b","evidence_kind":"source_excerpt","locator":"Lines 364-370","start_line":364,"end_line":370,"excerpt":"## red-yeast-rice-xuezhikang-events\nA specific extract had cardiovascular-outcome evidence in a defined population.\nOver an average 4.5 years, major coronary events occurred in 5.7% of the Xuezhikang group versus 10.4% of placebo in nearly 5,000 Chinese patients with prior myocardial infarction.\nModel: Randomized secondary-prevention trial; partially purified Xuezhikang preparation.\nLimitations: Not proof for arbitrary supplements, primary prevention or isolated pigment effects; event reduction is not itself a molecular mechanism.\nEvidence access: Primary abstract\n[18549841] Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction. · 2008 · https://pubmed.ncbi.nlm.nih.gov/18549841/ · DOI 10.1016/j.amjcard.2008.02.056","model_system":"Randomized secondary-prevention trial; partially purified Xuezhikang preparation.","directness":"reported_statement","verification_status":"source_derived_draft","notes":"Original curation paraphrase; evidence access and experimental limitations specified.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"261a12bc-3d00-52a4-a5ec-70e174390596","stable_key":"import-4910e17b-aaec-52cd-b9e5-caca85d817ee","title":"Red yeast rice: constituents, mevalonate, CoQ and product-specific interactions (2026-09-20)","document_type":"imported_text","citation_label":"AI-assisted research curation; primary references, access levels and experimental limitations individually identified. Not publisher full text.","file_path":"","sha256":"271bbcecaaacc76ad4d06718ae592dc6a1b33e3e459adfdd36cbd0ac5f09c0f6","revision_id":"9c30956c-206c-5c49-ae42-81b070088e26","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}